Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risk from leukemia drugs under the microscope

NCT ID NCT05724121

Recruiting now Knowledge-focused Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand and identify heart problems early in patients on these treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

BTK inhibitors or venetoclax

What this could lead to

If successful, this study could help doctors better monitor and prevent heart rhythm problems in people taking BTK inhibitors for blood cancers.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly benefit participants. It may not find clear links or lead to immediate changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation B-cell chronic lymphocytic leukemia cardiac rhythm disease Death, Sudden, Cardiac hematopoietic and lymphoid system neoplasm mantle cell lymphoma sudden arrhythmia death syndrome sudden cardiac arrest Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC ARRHYTHMIAS CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) HEMATOLOGIC MALIGNANCIES MANTLE CELL LYMPHOMA SUDDEN CARDIAC DEATH WALDENSTR(SQRROOT)(DELTA)M S MACROGLOBULINEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••